^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    asandeutertinib (TY-9591)

    i
    Other names: TY-9591, TY 9591
    Associations

    News

    Trials
    Company:
    TYK Medicines
    Drug class:
    EGFR inhibitor
    Related drugs:
    Associations

    News

    Trials
    11d
    A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, TYK Medicines, Inc
    New P2 trial • Metastases
    |
    cisplatin • carboplatin • pemetrexed • asandeutertinib (TY-9591)
    9ms
    Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects (clinicaltrials.gov)
    P1, N=48, Recruiting, TYK Medicines, Inc
    New P1 trial
    |
    itraconazole • asandeutertinib (TY-9591) • rifampicin
    10ms
    Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, TYK Medicines, Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    asandeutertinib (TY-9591)
    12ms
    A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation (clinicaltrials.gov)
    P1, N=105, Completed, TYK Medicines, Inc | Recruiting --> Completed
    Trial completion • Metastases
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR T790M
    |
    asandeutertinib (TY-9591)
    12ms
    [14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects (clinicaltrials.gov)
    P1, N=10, Recruiting, TYK Medicines, Inc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    asandeutertinib (TY-9591)
    1year
    TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases (clinicaltrials.gov)
    P2, N=420, Recruiting, TYK Medicines, Inc | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • asandeutertinib (TY-9591)
    over1year
    TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases (clinicaltrials.gov)
    P2, N=420, Not yet recruiting, TYK Medicines, Inc
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • asandeutertinib (TY-9591)
    over1year
    TY-0584: A potent, orally available small molecule YAP/TEAD inhibitor, exhibits anti-tumor effects in vitro and in vivo (AACR 2023)
    Therefore, small molecules that target palmitoylation of TEAD have been explored and VT3989 (NCT04665206) and IK-930 (NCT05228015) have success to enter the clinical trials...In line with the results of the in-vitro experiments, another YAP/TEAD inhibitor TY-0536 in combination with TY-9591 significantly delay the tumor regrowth in the PC9 CDX mouse model...[Shengli Dong and Apeng Liang contributed equally to this work. Jun Li, Shengli Dong, and Apeng Liang are the corresponding authors.]
    Preclinical
    |
    NF2 (Neurofibromin 2)
    |
    NF2 deletion
    |
    IK-930 • TY-0584 • VT3989 • asandeutertinib (TY-9591)
    almost2years
    A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation (clinicaltrials.gov)
    P1, N=126, Recruiting, TYK Medicines, Inc | Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Jun 2022 --> Mar 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR T790M
    |
    asandeutertinib (TY-9591)
    almost2years
    Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) (clinicaltrials.gov)
    P3, N=680, Recruiting, TYK Medicines, Inc | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • asandeutertinib (TY-9591)
    over2years
    Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) (clinicaltrials.gov)
    P3, N=680, Not yet recruiting, TYK Medicines, Inc
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • asandeutertinib (TY-9591)
    over4years
    A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation (clinicaltrials.gov)
    P1, N=126, Recruiting, TYK Medicines, Inc | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR exon 19 deletion • EGFR T790M
    |
    asandeutertinib (TY-9591)